Do you have stage III colon cancer? Have you already completed surgery? If so, you may qualify for a study that uses a blood test called ctDNA to determine your treatment and to monitor for recurrence.

Have you been diagnosed with high-risk, relapsed or relapsed/refractory Multiple Myeloma and have already received 1-3 different types of therapy? If so, you may be eligible for our phase 2 study of Selinexor, Daratumumab, Carfilzomib and Dexamethasone.

Have you been diagnosed with urothelial carcinoma? If so, you may be able to take part in a research study evaluation of an investigational treatment called FX-909 in cancer patients.

Have you been diagnosed with Liver cancer. If so, you may be able to take part in a research study looking to to measure the efficacy and safety of durvalumab IV solution plus bevacizumab IV solution after transarterial radioembolization(Y90 glass microsphere TARE) in participants with unresectable HCC amenable to locoregional therapy

Are you overweight or obese? If you also have heart disease or kidney disease with at least two risk factors for carviovascular disease, you might be eligible to take part in a research study that may help you reach up to 19% weight loss. In this study, we want to learn if a drug that is being tested is effective in reducing heart disease risks and will help you reach a healthier weight and active lifestyle.

Are you a non-drinker? Are you physically active or do you tend to sit a lot? If you're interested in learning about how alcohol use and physical activity may affect your health, you may be able to participate in our research study that includes two in-person study visits and a 21-day monitoring period. Compensation provided.

Do you have advanced or metastatic non small cell lung cancer, squamous cell carcinoma of the head and neck, colorectal cancer, or renal cell carcionma? Have you tried previous therapies that did not work? If so, you may be able to take part in this study. Investigational study drug is provided.

Do you have triple negative breast cancer? Have you had surgery following chemotherapy? You may be able to participate in a study to find out if stopping pembrolizumab infusions after surgery is just as effective at reducing your risk of cancer recurrence.

Help shape the future of lupus! Do you want to provide a game-changing contribution to lupus-centered research? Help us make clinical research more efficient and effective. If you have lupus, you can participate by providing samples we can study, such as blood, urine, saliva, and/or stool, to help doctors combat lupus head-on. Compensation provided.

Have you been diagnosed with B-cell post-transplant lymphoproliferative disorder (PTLD) after an organ transplant? Have you not yet received any type of treatment for this condition? Then you may be eligible for a study to look at the safety and effectiveness of tafasitamab and rituximab combination treatment for PTLD.